Frankfurt
18.12.25 | 08:03
0,062 Euro
-13,38 % -0,010
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,059 | 0,084 | 12:19 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11:42 | Ventripoint Diagnostics Ltd (2): Ventripoint to issue 1.1M shares for debenture interest | 1 | Stockwatch | ||
| 03:34 | Ventripoint Diagnostics Ltd.: Ventripoint to Issue Shares for Payment of Debenture Interest | 1 | TheNewswire | ||
| Di | Ventripoint Diagnostics Ltd (2): Ventripoint $567,000 debenture private placement | 1 | Stockwatch | ||
| Fr | Stocks in Play: Ventripoint Diagnostics Ltd | 1 | Baystreet.ca | ||
| Fr | Ventripoint Diagnostics Ltd.: Ventripoint Unveils a Global Model for A.I.-Enhanced Heart Care through Partnership with the Nisga'a Valley Health Authority | 1 | TheNewswire | ||
| 03.12. | Ventripoint Diagnostics Ltd (2): Ventripoint appoints Swetlow as CFO | 1 | Stockwatch | ||
| VENTRIPOINT DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 03.12. | Ventripoint Diagnostics appoints David Swetlow as CFO | 1 | Seeking Alpha | ||
| 03.12. | Ventripoint Diagnostics Ltd.: Ventripoint Diagnostics Announces Appointment of David Swetlow as Chief Financial Officer | 2 | TheNewswire | ||
| 27.11. | CEO.CA Technologies Ltd.: CEO.CA's Inside the Boardroom: Ventripoint Diagnostics: We Made Ultrasound as Good as MRI - Now Here's How We Scale It | 246 | Newsfile | Toronto, Ontario--(Newsfile Corp. - November 27, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining... ► Artikel lesen | |
| 07.11. | Ventripoint Diagnostics Ltd (2): Ventripoint arranges $542,591 debt settlement | 1 | Stockwatch | ||
| 06.11. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Debt Settlement Agreements | 2 | TheNewswire | ||
| 29.10. | Ventripoint Diagnostics Ltd (2): Ventripoint to test AI-enhanced echocardiography | 1 | Stockwatch | ||
| 29.10. | Ventripoint Diagnostics Ltd.: Ventripoint Diagnostics and Providence Health Care Ventures Announce Collaboration to Validate AI-Enabled Cardiac Imaging at St. Paul's Hospital | 1 | TheNewswire | ||
| 24.10. | Ventripoint Diagnostics Ltd (2): Ventripoint talks VMS+, sales expansion, partnerships | 2 | Stockwatch | ||
| 24.10. | Ventripoint Diagnostics Ltd.: Ventripoint Provides Corporate Update and Announces Shareholder Teleconference | 1 | TheNewswire | ||
| 14.10. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Closing of Second and Final Tranche of Non-Brokered Convertible Debenture Units Private Placement | 1 | TheNewswire | ||
| 03.10. | Ventripoint Diagnostics Ltd (2): Ventripoint to extend, increase debenture financing | 2 | Stockwatch | ||
| 03.10. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Extension and Up Size of Non-Brokered Convertible Debenture Unit Private Placement | 2 | TheNewswire | ||
| 19.09. | Ventripoint Diagnostics Ltd (2): Ventripoint Diagnostics completes annual quality audit | 1 | Stockwatch | ||
| 19.09. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Successful Completion of Key Quality Audits | 2 | TheNewswire |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ATOSSA THERAPEUTICS | 0,608 | 0,00 % | Atossa Therapeutics Inc: Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy | Designation expands (Z)-Endoxifen program into rare pediatric neuromuscular disease and may qualify Atossa for a future Priority Review Voucher upon approval
SEATTLE... ► Artikel lesen | |
| TANDEM DIABETES | 19,070 | -0,21 % | Tandem Diabetes upgraded, Zimmer, ResMed downgraded as Baird previews MedTech in 2026 | ||
| VERU | 2,220 | 0,00 % | Veru Inc.: Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress | -- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an... ► Artikel lesen | |
| MOLINA HEALTHCARE | 138,35 | +0,04 % | Analyse der Medicaid-Schadenquote: Jefferies reduziert Kursziel für Molina Healthcare | ||
| CLOVER HEALTH INVESTMENTS | 2,319 | +4,88 % | Clover Health Investments, Corp.: Clover Health Announces Chelsea Clinton to Step Down from Board Following Eight Years of Service | WILMINGTON, Del., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover," "Clover Health" or the "Company") today announced that Chelsea Clinton, the longest-serving... ► Artikel lesen | |
| SEMLER SCIENTIFIC | 14,400 | -0,69 % | Semler Scientific, Inc. - 8-K, Current Report | ||
| SOMNIGROUP INTERNATIONAL | 75,50 | -2,58 % | Somnigroup International: Somnigroup Proposes to Acquire Leggett & Platt in All-Stock Transaction | Proposal represents 30.3% premium to the average closing price of Leggett & Platt's shares during the last 30 trading days
Combination would provide Leggett &... ► Artikel lesen | |
| SINTX TECHNOLOGIES | 3,510 | -1,68 % | SiNtx Technologies, Inc.: SINTX Technologies unterzeichnet Liefervertrag mit EVONIK zur Herstellung eines Siliziumnitrid-PEEK-Verbundwerkstoffes für KI-gestützte, 3D-gedruckte patientenspezifische Implantate | Ein Meilenstein, der die sofortige Produktion von maßgefertigten SiN/PEEK-Implantaten ermöglichtSALT LAKE CITY, Utah, Dec. 01, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX"... ► Artikel lesen | |
| SHL TELEMEDICINE | - | - | Loyens & Loeff unterstützt SHL Telemedicine bei Kapitalerhöhung | ||
| SMILEDIRECTCLUB | - | - | Align Technology Settles Antitrust Lawsuit Over SmileDirectClub Deal for $31.75 Million | ||
| NEURONETICS | 1,340 | +1,21 % | Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan | Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of... ► Artikel lesen | |
| MEDLINE | 40,450 | 0,00 % | Aktien New York: Nasdaq schwach nach starkem Jahr - Medline-Börsengang im Blick | NEW YORK (dpa-AFX) - Die US-Börsen haben am Mittwoch erneut nachgegeben. Die Wall Street und vor allem die technologielastige Nasdaq zollten ihrem starken Lauf im Jahr 2025 weiter Tribut. Sorgen über... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 35,590 | 0,00 % | BrightSpring upgraded at KeyBanc on specialty pharmacy and EBITDA prospects | ||
| HEARTBEAM | 3,060 | 0,00 % | Heartbeam stock is a buy, this analyst says | ||
| PROGYNY | 26,010 | 0,00 % | Progyny, Inc. - 8-K, Current Report |
VENTRIPOINT DIAGNOSTICS LTD gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,062 Euro und damit -13,38 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VENTRIPOINT DIAGNOSTICS LTD finden Sie auf Wallstreet Online.